Cargando…
The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border?
Introduction: Glucocorticoid-induced myopathy is the sign of Cushing’s syndrome in 83%, but can also be consequence of exogenous administration of glucocorticoids. The patients with the compromised neuromuscular system (for example, because of myasthenia gravis) have a higher risk of this complicati...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089965/ http://dx.doi.org/10.1210/jendso/bvab048.324 |
_version_ | 1783687167491440640 |
---|---|
author | Dzherieva, Irina Brovkina, Snezhana Volkova, Natalia Davidenko, Ilia Reshetnikov, Igor Yudin, Maxim Plyashkevich, Maria Merenkova, Maria |
author_facet | Dzherieva, Irina Brovkina, Snezhana Volkova, Natalia Davidenko, Ilia Reshetnikov, Igor Yudin, Maxim Plyashkevich, Maria Merenkova, Maria |
author_sort | Dzherieva, Irina |
collection | PubMed |
description | Introduction: Glucocorticoid-induced myopathy is the sign of Cushing’s syndrome in 83%, but can also be consequence of exogenous administration of glucocorticoids. The patients with the compromised neuromuscular system (for example, because of myasthenia gravis) have a higher risk of this complication. Differential diagnosis of glucocorticoid-induced myopathy is challenging. Clinical case. A 77-year woman complained of difficulty in the act of breathing, swallowing, weakness in the limbs, inability to self-service, ptosis. Due to the growing complaints the patient was hospitalized to ICU. From anamnesis: She was diagnosed with myasthenia gravis 2 months ago. The presence of autoantibodies to the nicotine acetylcholine receptor was confirmed. Pyridostigmine bromide 60 mg/day, Methylprednisolone 20 mg/day were prescribed for 5 days. The patient noted some improvement. After the next neurologist’s examination the dose of Methylprednisolone was doubled. (It is not known for certain whether the doctor wanted to reduce the dose and the patient misunderstood.) She noted some worsening: weakness and speech difficulties increased. She returned to the previous dose after 3 days, but there was no improvement. Objectively: hypersthenic body type, BMI 39 kg/m2, predominant deposition of adipose tissue in the abdomen and face. Breathing without a ventilator. BP 250/100 mm Hg, heart rate 87 BPM. Laboratory tests revealed hyperkalemia of 8.76 mmol/l (3.5–5), creatinine of 481 mmol/l (44–124), hyperglycemia of 16 mmol/l. Glucocorticoid-induced myopathy was suspected, the administration of methylprednisolone was cancelled. The improvement of the condition was noted in 3 days. Blood pressure, glycaemia, levels of potassium and creatinine returned to normal. A biopsy of muscle revealed: atrophy of type I and II muscle fibers. There were no signs of necrosis, regeneration or inflammation. Thereby the diagnosis of glucocorticoid-induced myopathy was confirmed. Conclusion. Glucocorticoid-induced myopathy may look like a decompensation of neuromuscular disease. Since there are no accurate diagnostic tests nowadays the main argument of diagnosis is the paradoxical reaction after increasing the dose of glucocorticoids as well in this case. Even a short period of use of these drugs can lead to the development of side effects. It is necessary to regularly monitor the dynamics of the condition of such patients. |
format | Online Article Text |
id | pubmed-8089965 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-80899652021-05-06 The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border? Dzherieva, Irina Brovkina, Snezhana Volkova, Natalia Davidenko, Ilia Reshetnikov, Igor Yudin, Maxim Plyashkevich, Maria Merenkova, Maria J Endocr Soc Adrenal Introduction: Glucocorticoid-induced myopathy is the sign of Cushing’s syndrome in 83%, but can also be consequence of exogenous administration of glucocorticoids. The patients with the compromised neuromuscular system (for example, because of myasthenia gravis) have a higher risk of this complication. Differential diagnosis of glucocorticoid-induced myopathy is challenging. Clinical case. A 77-year woman complained of difficulty in the act of breathing, swallowing, weakness in the limbs, inability to self-service, ptosis. Due to the growing complaints the patient was hospitalized to ICU. From anamnesis: She was diagnosed with myasthenia gravis 2 months ago. The presence of autoantibodies to the nicotine acetylcholine receptor was confirmed. Pyridostigmine bromide 60 mg/day, Methylprednisolone 20 mg/day were prescribed for 5 days. The patient noted some improvement. After the next neurologist’s examination the dose of Methylprednisolone was doubled. (It is not known for certain whether the doctor wanted to reduce the dose and the patient misunderstood.) She noted some worsening: weakness and speech difficulties increased. She returned to the previous dose after 3 days, but there was no improvement. Objectively: hypersthenic body type, BMI 39 kg/m2, predominant deposition of adipose tissue in the abdomen and face. Breathing without a ventilator. BP 250/100 mm Hg, heart rate 87 BPM. Laboratory tests revealed hyperkalemia of 8.76 mmol/l (3.5–5), creatinine of 481 mmol/l (44–124), hyperglycemia of 16 mmol/l. Glucocorticoid-induced myopathy was suspected, the administration of methylprednisolone was cancelled. The improvement of the condition was noted in 3 days. Blood pressure, glycaemia, levels of potassium and creatinine returned to normal. A biopsy of muscle revealed: atrophy of type I and II muscle fibers. There were no signs of necrosis, regeneration or inflammation. Thereby the diagnosis of glucocorticoid-induced myopathy was confirmed. Conclusion. Glucocorticoid-induced myopathy may look like a decompensation of neuromuscular disease. Since there are no accurate diagnostic tests nowadays the main argument of diagnosis is the paradoxical reaction after increasing the dose of glucocorticoids as well in this case. Even a short period of use of these drugs can lead to the development of side effects. It is necessary to regularly monitor the dynamics of the condition of such patients. Oxford University Press 2021-05-03 /pmc/articles/PMC8089965/ http://dx.doi.org/10.1210/jendso/bvab048.324 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Adrenal Dzherieva, Irina Brovkina, Snezhana Volkova, Natalia Davidenko, Ilia Reshetnikov, Igor Yudin, Maxim Plyashkevich, Maria Merenkova, Maria The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border? |
title | The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border? |
title_full | The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border? |
title_fullStr | The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border? |
title_full_unstemmed | The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border? |
title_short | The Case of a Glucocorticoid-Induced Myopathy & Myasthenia Gravis Combination: Is There a Border? |
title_sort | case of a glucocorticoid-induced myopathy & myasthenia gravis combination: is there a border? |
topic | Adrenal |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089965/ http://dx.doi.org/10.1210/jendso/bvab048.324 |
work_keys_str_mv | AT dzherievairina thecaseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT brovkinasnezhana thecaseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT volkovanatalia thecaseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT davidenkoilia thecaseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT reshetnikovigor thecaseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT yudinmaxim thecaseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT plyashkevichmaria thecaseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT merenkovamaria thecaseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT dzherievairina caseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT brovkinasnezhana caseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT volkovanatalia caseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT davidenkoilia caseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT reshetnikovigor caseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT yudinmaxim caseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT plyashkevichmaria caseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder AT merenkovamaria caseofaglucocorticoidinducedmyopathymyastheniagraviscombinationisthereaborder |